NICE Recommends Ixazomib for Multiple Myeloma Through CDF

December 19, 2017 – The United Kingdom’s National Institute for Health and Care Excellence (NICE) has issued guidance recommending ixazomib in for patients with relapsed/refractory multiple myeloma. The proteasome inhibitor developed by Takeda is indicated for use in combination with lenalidomide and dexamethasone for patients who have already undergone 2 or 3 prior lines of therapy. The drug would be made available through the Cancer Drugs Fund (CDF) … (leggi tutto)